Breaking News

Tweet TWEET

Dyax Corp. Announces Presentation of KALBITOR® (ecallantide) Pediatric and Abdominal Attack Data at the American College of

  Dyax Corp. Announces Presentation of KALBITOR® (ecallantide) Pediatric and
  Abdominal Attack Data at the American College of Allergy, Asthma and
  Immunology Annual Meeting (ACAAI)

Business Wire

BURLINGTON, Mass. -- November 13, 2012

Dyax Corp. (NASDAQ: DYAX) announced today that two poster presentations
featuring updated KALBITOR^® (ecallantide) data in pediatric patients with
hereditary angioedema (HAE) and HAE patients with abdominal attacks were
presented at the American College of Allergy, Asthma and Immunology (ACAAI)
2012 Annual Scientific Meeting, held November 8-13, at the Anaheim Convention
Center in Anaheim, CA. Both presentations pooled results from patients
enrolled in four different clinical trials of ecallantide for the treatment of
acute HAE attacks: DX-88/19, an open-label continuation study; EDEMA2^®, an
open-label, Phase 2 dose-ranging, repeat-dosing study; and EDEMA3^® and
EDEMA4^®, two Phase 3 double-blind, placebo-controlled studies. KALBITOR is
indicated for the treatment of acute attacks of HAE in patients 16 years of
age and older.

Commenting on the study “Clinical Trial Experience of Pediatric Patients
Treated with Ecallantide for Acute Attacks of Hereditary Angioedema,” Andrew
MacGinnitie, MD, PhD, Associate Clinical Director, Division of Immunology at
Boston Children’s Hospital, and lead investigator of the study, stated: “In
order to provide patients with effective relief from the disease’s often
debilitating, acute attacks, it is important that pediatric and other
specialist communities learn to diagnose and treat HAE as early as possible.”

“Our clinical studies of KALBITOR reinforce its demonstrated ability to
effectively treat various patient populations and attack locations,” commented
Dr. Burt Adelman, Executive Vice President and Chief Medical Officer at Dyax
Corp. “The presentation of these data is part of our ongoing effort to educate
the healthcare community about hereditary angioedema and novel treatments such
as KALBITOR. Dyax remains committed to providing an HAE support, education and
treatment awareness program that is second to none.”

Complete List of Poster Presentations on KALBITOR at ACAAI 2012

Poster Presentations

  *Clinical Trial Experience of Pediatric Patients Treated with Ecallantide
    for Acute Attacks of Hereditary Angioedema – Andrew MacGinnitie, MD, PhD,
    Associate Clinical Director, Division of Immunology, Boston Children’s
    Hospital, Boston, MA, Poster P303 presented on Saturday, November 10,
    12:30-1:30p.m. PST and Sunday, November 11, 12:00-1:00p.m. PST
  *Treatment of Abdominal Attacks of Hereditary Angioedema with Ecallantide –
    Christopher Stevens, MD, Gastroenterology Medical Consultant, Poster P305
    presented on Saturday, November 10, 12:30-1:30p.m. PST and Sunday,
    November 11, 12:00-1:00p.m. PST

About KALBITOR^® (ecallantide)
KALBITOR is a plasma kallikrein inhibitor indicated for the treatment of acute
attacks of hereditary angioedema (HAE) in patients 16 years of age and older.
KALBITOR, which was discovered and developed by Dyax, is the first
subcutaneous treatment available in the U.S. for treating acute HAE attacks.

Important KALBITOR Safety Information
Anaphylaxis has been reported after administration of KALBITOR. Because of the
risk of anaphylaxis, KALBITOR should only be administered by a healthcare
professional with appropriate medical support to manage anaphylaxis and
hereditary angioedema. Healthcare professionals should be aware of the
similarity of symptoms between hypersensitivity reactions and hereditary
angioedema and patients should be monitored closely. KALBITOR should not be
administered to patients with known clinical hypersensitivity to KALBITOR.

As part of product approval, Dyax has implemented a Risk Evaluation and
Mitigation Strategy (REMS) program. The goal of the REMS is to communicate the
risk of anaphylaxis and the importance of distinguishing between a
hypersensitivity reaction and HAE attack symptoms.

For more information about KALBITOR, including full prescribing information,
visit www.KALBITOR.com.

KALBITOR Development HAE Program
The approval of KALBITOR is based on the results of two placebo-controlled
Phase 3 clinical studies, known as EDEMA3^® and EDEMA4^®. Patients having an
attack of HAE, at any anatomic location, with at least one moderate or severe
symptom, were treated with 30 mg subcutaneous KALBITOR or placebo. Because
patients could participate in both trials, a total of 143 unique patients
participated. There were 64 patients with abdominal attacks, 55 with
peripheral attacks, and 24 with laryngeal attacks. In both trials, the effects
of KALBITOR were evaluated using the Mean Symptom Complex Severity (MSCS)
score and the Treatment Outcome Score (TOS), two HAE-specific patient-reported
outcome endpoints developed by Dyax. These measures evaluated the severity of
attack symptoms at all anatomical locations (MSCS score) and response to
therapy (TOS). In the EDEMA4 trial at 4 hours, patients treated with KALBITOR
demonstrated a greater decrease from baseline in the mean MSCS than placebo
(-0.8 vs. -0.4; p = 0.010) and a greater mean TOS (53 vs. 8, p = 0.003). In
the EDEMA4 trial at 24 hours, patients treated with KALBITOR also demonstrated
a greater decrease from baseline in the mean MSCS than placebo (-1.5 vs. -1.1;
p = 0.04) and a greater mean TOS (89 vs. 55, p = 0.03). The results in the
EDEMA3 trial were consistent with the EDEMA4 trial results.

Potentially serious hypersensitivity including anaphylaxis, have occurred in
patients treated with KALBITOR. In 255 HAE patients treated with intravenous
or subcutaneous KALBITOR in clinical studies, 10 patients (3.9%) experienced
anaphylaxis. For the subgroup of 187 patients treated with subcutaneous
KALBITOR, 5 patients (2.7%) experienced anaphylaxis. Symptoms associated with
these reactions have included chest discomfort, flushing, pharyngeal edema,
pruritus, rhinorrhea, sneezing, nasal congestion, throat irritation,
urticaria, wheezing, and hypotension. These reactions occurred within the
first hour after dosing.

The most common adverse reactions occurring in greater-than or equal to 3% of
KALBITOR-treated patients and greater than placebo were headache, nausea,
diarrhea, pyrexia, injection site reactions, and nasopharyngitis.

KALBITOR Access^®
Patients and healthcare providers can contact KALBITOR Access^® to receive
information and work with program staff to research patient insurance coverage
for KALBITOR. KALBITOR Access is designed as a one-stop point of contact for
information about KALBITOR. The program is staffed with dedicated insurance
specialists and nurse case managers who will help coordinate patient treatment
and access to KALBITOR. Patients and healthcare providers can call
1-888-4KALBITOR (1-888-452-5248) for information and to utilize these services
or visit www.KALBITOR.com.

About HAE
Hereditary angioedema (HAE) is a rare acute inflammatory condition
characterized by episodes of severe, often painful swelling affecting the
extremities, gastrointestinal tract, genitalia, and larynx. HAE is caused by
low or dysfunctional levels of C1 esterase inhibitor (C1-INH), a naturally
occurring molecule that inhibits plasma kallikrein, a key mediator of
inflammation, and other serine proteases in the blood. HAE is estimated to
affect 1 in 10,000 to 1 in 50,000 individuals. Learn more at www.HAEHope.com.

About Dyax
Dyax is a fully integrated biopharmaceutical company focused on the discovery,
development and commercialization of novel biotherapeutics for unmet medical
needs. The Company’s key value drivers are the KALBITOR^® (ecallantide)
business and the angioedema portfolio, as well as the Licensing and Funded
Research Program (LFRP).

Dyax developed KALBITOR on its own and, since February 2010, the Company has
been selling it in the United States for the treatment of acute attacks of
hereditary angioedema (HAE) in patients 16 years of age and older. Outside the
United States, the Company has established partnerships to obtain regulatory
approval for and commercialization of KALBITOR in certain markets and is
evaluating opportunities in others.

The Company is currently developing products to expand its angioedema
portfolio, including a diagnostic strategy to identify plasma kallikrein
(bradykinin) mediated (PKM) angioedema and a therapeutic candidate, DX-2930,
for the prophylactic treatment of PKM angioedema.

KALBITOR and DX-2930 were identified using Dyax’s patented phage display
technology, which rapidly selects compounds that bind with high affinity and
specificity to therapeutic targets. Dyax leverages this technology broadly
through the LFRP. This program has provided the Company a portfolio of product
candidates being developed by its licensees, which currently includes11
royalty and/or milestone bearing product candidates in various stages of
clinical development, including three in Phase 3 trials.

Dyax is headquartered in Burlington, Massachusetts. For additional information
about Dyax, please visit www.dyax.com.

Dyax Disclaimer
This press release contains forward-looking statements, including statements
regarding the prospects for therapeutic benefits and treatment advantages of
KALBITOR for HAE. Statements that are not historical facts are based on Dyax's
current expectations, beliefs, assumptions, estimates, forecasts and
projections about the industry and markets in which Dyax competes. The
statements contained in this release are not guarantees of future performance
and involve certain risks, uncertainties and assumptions, which are difficult
to predict. Therefore, actual outcomes and results may differ materially from
what is expressed in such forward-looking statements. Important factors which
may affect the prospects for therapeutic benefits and treatment advantages of
KALBITOR for HAE include the risks that: others may develop products superior
to KALBITOR; KALBITOR may not gain market acceptance; Dyax is dependent on the
expertise, effort, priorities and contractual obligations of third parties in
the manufacture, marketing, sales and distribution of KALBITOR; and other risk
factors described or referred to in Item 1A, "Risk Factors" in Dyax's most
recent Annual Report on Form 10-K and other periodic reports filed with the
Securities and Exchange Commission. Dyax cautions investors not to place undue
reliance on the forward-looking statements contained in this release. These
statements speak only as of the date of this release, and Dyax undertakes no
obligations to update or revise these statements, except as may be required by
law.

Dyax, the Dyax logo, KALBITOR, KALBITOR Access, EDEMA2, EDEMA3 and EDEMA4 are
registered marks of Dyax Corp.

Contact:

Dyax Corp.
Jennifer Robinson, 617-250-5741
Associate Director,
Investor Relations and Corporate Communications
jrobinson@dyax.com
 
Press spacebar to pause and continue. Press esc to stop.